结直肠癌筛查中结肠镜、粪便免疫化学检测与风险适配筛查参与率及诊断产出的比较:TARGET-C多中心随机对照试验中期分析
结果显示风险适配筛查参与率高且诊断产出优于FIT,而结肠镜诊断产出最高但参与率最低。
要点
- 风险适配筛查参与率85.2%,高于结肠镜42.5%,低于FIT 94.0%。
- 结肠镜进展期肿瘤检出率2.40%,高于风险适配筛查1.66%和FIT 1.13%。
- 风险适配筛查诊断产出优于FIT,且结肠镜负荷相近。
核心结论
- 基线筛查中风险适配筛查参与率高,诊断产出优于FIT且结肠镜负荷相似。
- 结肠镜进展期肿瘤检出率最高但参与率最低。
研究设计与样本
- 按1:2:2随机分入一次性结肠镜组(n=3,916)、年度FIT组(n=7,854)和年度风险适配筛查组(n=7,776)。
主要发现
- 基线筛查参与率:结肠镜组42.5%(1,665/3,916),FIT组94.0%(7,386/7,854),风险适配筛查组85.2%(6,628/7,776)。
- 意向性筛查分析进展期肿瘤检出率:结肠镜组2.40%(94/3,916),FIT组1.13%(89/7,854),风险适配筛查组1.66%(129/7,776)。
- 结肠镜 vs FIT 的OR(95%CI)为2.16(1.61-2.90),P<0.001。
- 结肠镜 vs 风险适配筛查的OR(95%CI)为1.45(1.10-1.90),P<0.001。
- 风险适配筛查 vs FIT 的OR(95%CI)为1.49(1.13-1.97),P<0.001。
关键数值与推荐
- 风险适配筛查依据风险分层评分,高风险者转诊结肠镜,低风险者转诊FIT。
- 所有FIT阳性者转诊诊断性结肠镜。
- 检出1例进展期肿瘤所需结肠镜检查人数:结肠镜组18人,FIT组10人,风险适配筛查组11人。
临床怎么用
- 风险适配筛查可作为提高参与率且维持较低结肠镜负荷的筛查策略。
- FIT参与率最高但进展期肿瘤检出率最低,需权衡诊断产出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In colorectal cancer screening, implementing risk-adapted screening might be more effective than traditional screening strategies. We aimed to compare the effectiveness of a risk-adapted screening strategy with colonoscopy and fecal immunochemical test (FIT) in colorectal cancer screening. METHODS: A randomized controlled trial was conducted in 6 centers in China since May 2018. Nineteen thousand five hundred forty-six eligible participants aged 50-74 years were recruited and randomly allocated into 1 of the 3 screening groups in a 1:2:2 ratio: (i) one-time colonoscopy (n = 3,916), (ii) annual FIT (n = 7,854), and (iii) annual risk-adapted screening (n = 7,776). Based on the risk-stratification score, high-risk subjects were referred for colonoscopy and low-risk ones were referred for FIT. All subjects with positive FIT were referred for diagnostic colonoscopy. The detection rate of advanced neoplasm was the primary outcome. The study is registered with the China Clinical Trial Registry (www.chictr.org.cn Identifier: ChiCTR1800015506). RESULTS: For baseline screening, the participation rates of the colonoscopy, FIT, and risk-adapted screening groups were 42.5% (1,665/3,916), 94.0% (7,386/7,854), and 85.2% (6,628/7,776), respectively. For the intention-to-screen analysis, the detection rates of advanced neoplasm were 2.40% (94/3,916), 1.13% (89/7,854), and 1.66% (129/7,776), with odds ratios (95% confidence intervals) of 2.16 (1.61-2.90; P < 0.001) for colonoscopy vs FIT, 1.45 (1.10-1.90; P < 0.001) for colonoscopy vs risk-adapted screening, and 1.49 (1.13-1.97; P < 0.001) for risk-adapted screening vs FIT, respectively. The numbers of subjects who required a colonoscopic examination to detect 1 advanced neoplasm were 18 in the colonoscopy group, 10 in the FIT group, and 11 in the risk-adapted screening group. DISCUSSION: For baseline screening, the risk-adapted screening approach showed a high participation rate, and its diagnostic yield was superior to that of FIT at a similarly low load of colonoscopy.
引用
- Chen H, Lu M, Liu C, et al. Comparative Evaluation of Participation and Diagnostic Yield of Colonoscopy vs Fecal Immunochemical Test vs Risk-Adapted Screening in Colorectal Cancer Screening: Interim Analysis of a Multicenter Randomized Controlled Trial (TARGET-C). Am J Gastroenterol. 2020. PMID: 32282342. doi:10.14309/ajg.0000000000000624
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。